Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Our "Peanut Allergy" Biotech IPO Debuts Today

Aimmune Therapeutics Inc. (Nasdaq: AIMT), the Brisbane, Calif.-based biotech that's developed one of the first true treatments for peanut-allergy sufferers, is scheduled to make its public debut today.

The firm's shares are supposed to start trading today after an initial public offering (IPO) of 8.33 million shares in a price range of $14 a share to $16 a share.

Although we don't often recommend IPO stocks, we made an exception here in a special report we gave you back on July 27. Aimmune is a development-stage biotech, but its lead product is about to enter late-stage clinical trials.

With the stock scheduled to begin trading today, let's take another look at the firm, its lead product - and the market it's looking to serve.

Full Story
  1. kai Tastula | August 9, 2015

    No comments good stories.

Leave a Reply

Your email address will not be published. Required fields are marked *

Some HTML is OK